Johnson & Johnson strikes $1 billion deal to buy Firefly Bio, betting on a next-gen KRAS strategy

Johnson & Johnson said on Monday it has entered into a definitive agreement to acquire Firefly Bio, a cancer drug developer, in a $1 billion cash deal. The deal is designed to strengthen Johnson & Johnson’s oncology pipeline with a proprietary platform aimed at attacking KRAS-driven tumors, a strategy the company framed as part of a broader push to expand targeted therapies for hard-to-treat solid cancers.

Under the terms of the agreement, Johnson & Johnson will pay $1 billion in cash for Firefly Bio. The company expects the transaction to close later this year, subject to regulatory approvals and customary closing conditions. Johnson & Johnson did not provide an exact expected closing date, and it said it will communicate the accounting treatment on or before the close.

Firefly Bio’s core asset, according to Johnson & Johnson, is its Firelink degrader antibody conjugate platform (often shortened to DAC). In plain terms, the approach combines an antibody targeting element with a “protein degrader” payload, with the goal of delivering a highly selective degradative effect to tumor cells while avoiding effects on healthy cells. Johnson & Johnson said the platform is designed to target pan-KRAS and other drivers of hard-to-treat cancers.

In its statement, Johnson & Johnson said the Firelink DAC platform is intended to overcome limitations of existing therapeutic approaches for KRAS-driven cancers. The company also said it expects the acquisition to diversify its pipeline with preclinical candidates for treating multiple types of solid tumors with high unmet need. Johnson & Johnson did not identify specific programs, molecules, or indications tied to Firefly Bio beyond its KRAS focus.

John Reed, M.D., Ph.D., Johnson & Johnson’s executive vice president for Innovative Medicine Research & Development, said KRAS has been viewed as notoriously difficult to drug and that patients with KRAS-driven cancers continue to face limited treatment options. He added that Johnson & Johnson believes the Firelink platform could overcome limitations of current treatments and broaden the company’s pipeline with preclinical candidates.

The acquisition reinforces Johnson & Johnson’s long-running emphasis on oncology and antibody-based science. The company said it has advanced innovative cancer therapies for more than three decades, and it positioned Firefly Bio’s capabilities in emerging modalities as complementary to its existing expertise in antibody engineering. In addition to acquiring individual candidates, major drugmakers increasingly pay for platforms they believe can generate multiple pipeline assets over time.

The deal also arrives as investor and scientific attention remains intense around KRAS. In reporting published Monday, STAT said the acquisition came less than two months after Revolution Medicines disclosed results suggesting a KRAS-targeted approach could nearly double survival in metastatic pancreatic cancer. Johnson & Johnson’s announcement did not cite those results directly, but it placed KRAS at the center of the Firelink platform’s rationale.

As with many early-stage biotech acquisitions, Johnson & Johnson’s announcement leaves key specifics unstated. It did not disclose the current clinical stage of Firefly Bio’s programs, any data supporting the platform in humans, or the internal development timeline for the preclinical candidates it referenced. It also did not provide a breakdown of deal economics beyond the headline $1 billion cash figure or describe any contingent payments, milestones, or workforce-related disclosures. Those details, if any, typically emerge in later filings or transaction documentation. Closing is expected later this year, subject to approvals, which will be a key date for investors and competitors watching how regulators evaluate the combination and what commitments the parties make after sign-and-close.